Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
NCT04056910
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Advanced Solid Tumor
IDH1 Mutation
Glioma
Interventions
DRUG:
ivosidenib and nivolumab
Sponsor
Jason J. Luke, MD
Collaborators
[object Object]
[object Object]